Is Prednisolone Effective for All Kawasaki Disease Cases?

Understanding the Role of Steroids in Kawasaki Disease

Researchers recently investigated the impact of Prednisolone for Kawasaki Disease in a large clinical trial. Kawasaki disease causes significant inflammation of the blood vessels, which often leads to heart complications in children. Specifically, this condition can cause coronary artery lesions if clinicians do not treat it promptly. While intravenous immunoglobulin remains the standard care, experts continue to debate the necessity of adding glucocorticoids for every patient. This study provides crucial evidence regarding the efficacy of adjunctive steroids in an unselected patient population.

Efficacy of Prednisolone for Kawasaki Disease

The multicenter trial in China randomized over 3,000 children to receive either standard therapy alone or standard therapy plus prednisolone. However, the study results showed no significant reduction in the primary outcome of coronary artery lesions at one month. Specifically, researchers detected lesions in 16.0% of the prednisolone group compared to 13.8% of the control group. Consequently, adding steroids to the initial treatment did not prevent heart damage more effectively than standard care. These findings suggest that routine administration might not benefit all children with a new diagnosis. Furthermore, the incidence of giant coronary artery aneurysms at three months remained similar between both groups. Therefore, the evidence does not support the universal use of glucocorticoids for preventing long-term cardiac morbidity.

Secondary Benefits and Patient Safety

Despite the lack of benefit for heart lesions, the trial highlighted several secondary improvements. For instance, the prednisolone group experienced a significantly shorter duration of fever. Additionally, clinicians observed a more rapid reduction in C-reactive protein levels among these patients. Moreover, the group receiving steroids required substantially less rescue therapy compared to those on standard treatment alone. Specifically, only 4.6% of the steroid group needed additional interventions, while 10.1% of the control group required them. Consequently, while steroids do not necessarily protect the heart, they effectively control acute systemic inflammation. Importantly, the overall incidence of adverse events did not differ between the two groups, indicating a favorable safety profile for short-term use.

Clinical Implications for India

Indian pediatricians often encounter Kawasaki disease as a leading cause of acquired heart disease. Currently, the Indian Council of Medical Research guidelines prioritize intravenous immunoglobulin and aspirin for primary management. These guidelines generally reserve steroids for patients at high risk of treatment resistance or those with baseline heart abnormalities. This trial reinforces the current practice of being selective with steroid use. Since the addition of prednisolone did not improve heart outcomes in this unselected cohort, doctors should likely continue targeting high-risk individuals. Furthermore, maintaining focus on timely diagnosis and early standard treatment remains the most effective strategy for preventing coronary complications.

Frequently Asked Questions

Q1: Does prednisolone prevent heart damage in all Kawasaki disease patients?

No, the latest research indicates that adjunctive prednisolone does not significantly reduce the incidence of coronary artery lesions at one month when used in unselected patients.

Q2: What were the main benefits of using steroids in this study?

Patients who received steroids experienced a faster reduction in fever and required less rescue therapy. Additionally, their inflammatory markers decreased more rapidly compared to those receiving standard care alone.

Q3: Is the use of prednisolone safe for children with this condition?

Yes, the study found that the overall incidence of adverse events was similar between the groups, suggesting that the treatment is generally well-tolerated in the short term.

References

1. Lin S et al. Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease. N Engl J Med. 2026 Apr 16. doi: 10.1056/NEJMoa2511478. PMID: 41985133.
2. Indian Council of Medical Research. Standard Treatment Workflow: Kawasaki Disease. 2024.
3. Singh S et al. Diagnosis of Kawasaki disease. Int J Rheum Dis. 2018;21:36-44.